MedTrace Logo

Autologous Natural Killer Cells in Subjects With Plaque Psoriasis

NCT03894579 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-06-26

No results posted yet for this study

Summary

This is a non-randomized, dose escalating and open-labeled clinical trial to evaluate the safety of autologous natural killer cell (NK) infusions (IV) of "SNK01" in adults with plaque psoriasis. The primary objective of this study is to investigate the safety and tolerability of four infusions of "SNK01" in subjects with plaque psoriasis. Secondary objective is preliminary efficacy of "SNK01" in subjects with plaque psoriasis.

Conditions

Interventions

BIOLOGICAL

Study Product: SNK01

SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4

Sponsors & Collaborators

  • NKGen Biotech, Inc.

    lead INDUSTRY

Principal Investigators

  • Daniela Gutiérrez, MD · Hospital Angeles Tijuana

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-18
Primary Completion
2019-12-03
Completion
2019-12-03
FDA Drug
Yes

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03894579 on ClinicalTrials.gov